Preoperative factors predicting Postoperative Morbidity in patients with Periampullary Carcinoma undergoing Pancreaticoduodenectomy by Paranthaman, S
  
“PREOPERATIVE FACTORS PREDICTING  POSTOPERATIVE 
MORBIDITY IN PATIENTS WITH PERIAMPULLARY 
CARCINOMA UNDERGOING PANCREATICO 
DUODENECTOMY” 
 
Dissertation submitted to 
 
THE TAMILNADU Dr M.G.R MEDICAL UNIVERSITY 
 
In partial fulfilment  of the regulations for the award of the 
 
M.S.DEGREE EXAMINATION 
BRANCH – I 
GENERAL SURGERY 
 
 
 
 
 
 
 
 
 
 
 
 
STANLEY MEDICAL COLLEGE 
THE TAMIL NADU DR. M.G.R.MEDICAL UNIVERSITY  
CHENNAI 
 
APRIL– 2017  
 CERTIFICATE 
This is to certify that this dissertation on “PREOPERATIVE FACTORS 
PREDICTING POSTOPERATIVE MORBIDITY IN PATIENTS WITH 
PERIAMPULLARY CARCINOMA UNDER GOING PANCREATICO 
DUODENECTOMY” is a bonafide work done by Dr.S.PARANTHAMAN Post 
graduate student (2014- 2017) in the Department of General Surgery, Government  
Stanley Medical College & Hospital, Chennai under my direct guidance and 
supervision, in partial fulfilment of the regulations of the The Tamilnadu Dr.M.G.R. Medical 
University, Chennai for the award of  M.S., Degree (General Surgery) Branch-I, examination to be 
held in April 2017. 
 
 
 
 
 
 
 
PROF. Dr.C.BALAMURUGAN M.S.,      PROF.Dr.D.NAGARAJAN M.S., 
Professor of Surgery,  Professor and Head of the Department, 
Department of General Surgery,  Department of General Surgery, 
Govt. Stanley Medical College,  Govt. Stanley Medical College, 
Chennai – 1.                                                    Chennai-1. 
 
 
 
 
PROF .Dr. ISAAC CHRISTIAN MOSES  M.D., FICP., FACP., 
The Dean, 
Govt. Stanley Medical College, 
Chennai – 1. 
 
 
 
 DECLARATION 
I, Dr S PARANTHAMAN, solemnly declare that this dissertation titled 
“PREOPERATIVE FACTORS PREDICTING POSTOPERATIVE  
MORBIDITY IN PATIENTS WITH PERIAMPULLARY CARCINOMA 
UNDERGOING PANCREATICODUODENECTOMY”, is  a  bonafide work  
done by me, in the Department of General Surgery and surgical 
Gasteroenterology, Government Stanley Medical College & Hospital, 
Chennai under the guidance and supervision of my unit chief  PROF. 
Dr.C.BALAMURUGAN M.S., 
This dissertation is submitted to the Tamilnadu Dr.M.G.R. 
Medical University, Chennai in fulfilment of the University regulations 
for the award of  M.S., Degree (General Surgery) Branch – 1, 
examination to be held in April 2017. 
 
 
 
 
 
 
Place : 
Date :                                                                 Dr. S PARANTHAMAN 
  
 ACKNOWLEDGEMENT 
I sincerely thank with gratitude The Dean, Prof . Dr.ISAAC 
CHRISTIAN MOSES  M.D., FICP., FACP., Govt. Stanley Medical 
College, Chennai for having permitted me to carry out this study at 
Government Stanley Hospital, Chennai. 
 My special  thanks  goes  to  Prof. Dr. D.NAGARAJAN 
M.S., Professor and Head, Department of Surgery, Stanley Medical 
College, Chennai for his guidance throughout the period of my study. 
I am greatly indebted Prof. Dr. C. BALAMURUGAN M.S., my 
unit chief, who had been a constant source of encouragement and 
inspiration for the smooth completion of my study. 
I express my deepest sense of thankfulness to my assistant 
professors Dr.G.VENKATESH M.S., Dr.D.PRINCESS BUELAH 
M.S., Dr.M.VIGNESH M.S., for their immense help and guidance 
through out my study. 
I cannot forget the co-operation of my friends Dr.Srinivasan, 
Dr.Sivasankaran  in completing my study. I am also thankful to my 
seniors DrVarun Gandhi, Dr Prem Kumar, Dr Aravind, Dr Sabarimalai, 
Dr Ashok Kumar, Dr KitakaSukhataWotsa for their valuable support in 
this study. 
I could not forget to thank my juniors Dr.AnuHalan, 
Dr.Sivagovindan, Dr. Salahudeen, Dr. Kamalakannan , Dr. Aravind 
Ram, Dr.Chethan without whom accomplishing this task would have 
been impossible. 
  
 
 TABLE OF CONTENTS 
SL.NO. CONTENTS 
PAGE 
NO. 
1 INTRODUCTION 1 
2 AIM OF STUDY 3 
3 REVIEW OF LITERATURE 7 
4 MATERIALS AND METHODS 52 
5 MASTER CHART 54 
6 RESULTS 73 
7 SUMMARY  79 
8 CONCLUSION 81 
9 EHICAL COMMITTEE APPROVAL 82 
10 PROFORMA 83 
11 CONSENT 85 
12 BIBLIOGRAPHY 87 
   
 
  
1 
 
 
INTRODUCTION 
Periampullary carcinoma is a carcinoma that forms near the ampulla of vater, an 
enlargement of the ducts from the liver and pancreas where they join and enter 
the small intestine .It consists of: 
1.  ampullary.  ( ampulla of vater) 
2.  Biliary . (intrapancreatic distal bile duct) 
3.  Pancreatic. (head –Uncinate process) 
4.  Duodenal (mainly from the second portion) 
75% to 80% of periampullary carcinoma are well differentiated 
adenocarcinomas. Though, these tumors have different sites of orgin, the complex 
regional anatomy and their proximation with in that confined region , dictate  
common operative approach. 
Radical  resections,  such  as  the  whipple’s procedure or with preservation of 
the pylorus with or without extended regional lymphadenectomy, has been the main 
treatments for these cancers , especially with currently low morbidity and mortality 
rates. Although the perioperative outcomes for these different cancer are similar, the 
long term survival has traditionally varied. Consequently, the exact tumor origin is 
often difficult to clinically ascertain, surgeons have favored an aggressive approach 
toward resection to benefit those patients having cancers with a better prognosis. 
It is not known that outcome varies  for adenocarcinomas arising from 
different anatomic sites in such close proximity. Indeed, if survival does vary 
2 
 
 
significantly for those cancers as clinical impression suggests, clearly, factors other 
than anatomy must also  involved.  
Since  Periampullary carcinoma is one of the commonest cause of obstructive 
jaundice & highest cure rate following resection is possible, this study is undertaken 
to know the differences in  clinical behavior of  the Periampullary carcinoma and to 
define which of these factors, affect the disease outcome and alter the morbidity and 
survival. 
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AIM OF THE STUDY 
1.  To evaluate the incidence of Periampullary carcinoma in Stanley medical 
college from feb 2016 to sep 2016 
2.  To know the clinical manifestation  
3.  To know the investigations to aid the diagnosis and assess the respectability of 
these tumors. 
4  To know about the preoperative factors which determine the postoperative 
morbidity in patients undergoing whipples procedure 
5.  To study the treatment instituted and the management of complications 
6.  To review the literature on the subject. 
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MATERIALS AND METHODS: 
- The study is to be carried out in Govt .Stanley  Medical college hospital 
Chennai 
- This is a facility based prospective descriptive study involving all  patients 
diagnosed as periampullary carcinoma clinically, radiologically, and 
pathologically. The relevant data shall be collected by using. 
 Detailed history 
 Hematological investigations: complete hemogram, liver function test, serum 
proteins and albumin. 
 Coagulation profile – PT ,aPTT, INR 
 Blood culture & sensitivity Stool for occult blood 
 Imaging studies : Xray chest , X ray abdomen erect 
 USG abdomen & pelvis – to find liver, gallbladder, common bile duct, 
pancreas and duodenum lesions, 
 CT(Plain and contrast) abdomen &  pelvis /MRCP– to find exact location, 
size, extent of tumour. 
 Patients undergoing pancreaticoduodenectomy – pathologically proven 
carcinomatous lesions 
 Postoperative factors like ventillatory support, abdominal distention, 
coagulation profile, peritonitis, fever, sepsis, no of days of ICU stay, 
ionotropic support, biochemical derangements are taken into study. 
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PREOPERATIVE FACTORS INCLUDED IN STUDY 
• Age, 
• Tumour localization,  
• CA 19-9 levels 
• Preoperative bilirubin levels 
• Preoperative albumin levels 
•  ERCP and stenting  
• cholangitis  
POSTOPERATIVE FACTORS INCLUDED IN STUDY 
• Ventillatory support  
• Sepsis,  
• No of days of ICU stay, 
• Ionotropic support, 
• Biochemical derangements 
• relaporotomy 
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INCLUSION CRITERIA 
• All patients with periampullary carcinoma undergoing 
pancreaticoduodenectomy( whipple procedure) in Govt Stanley hospital 
EXCLUSION CRITERIA 
• Uncertain diagnosis and death 
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REVIEW OF LITERATURE 
EMBRYOLOGY 
The caudal foregut and the cranial midgut generate  the duodenum. The origin of the 
bileduct, the pancreas, and the ampulla of vater arise from the foregut just above its 
junction with the midgut. 
Embryologically and anatomically, patterns  of  periampullary  cancer spread 
should be similar for pancreatic, ampullary and distal bile duct cancers because they 
are foregut derivatives. In contrast, infra-ampullary duodenal cancers should spread 
along the superior mesenteric or midgut pathways. 
Because of the ambiguous lymphatic drainage of the head of pancreas, 
lymphatic metastases from pancreatic cancers are less predictable and are likely to 
extend along the foregut and midgut pathways. 
Invasion of the pancreas by non pancreatic periampullary cancers likely 
predisposes to similar patterns of spread. Because most periampullary cancers arise 
commonly from the distal foregut, anatomic or embryologic factors likely contribute 
little to differences in outcome. 
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SURGICAL ANATOMY 
PANCREAS 
Glandular and Retroperitoneal organ, transversely placed at L1 level (12–
20cmlong, 60–125gwt),and has close  proximity to many organs and great vessels 
leads to early local invasion Related to omentalbursa above and greater sac below, 
Anterior–transverse mesocolon, Posterior–avscular fusion planes of Toldt and Treitz. 
Arbitrarily divided into head, neck, body &tail  
• Head –  Rt. of SMV (45—50% of gland) 
• Neck –  on Superior Mesenteric Vessels 
• Body& tail – lateral toLt. Bolder of SMV 
• Uncinate  process. 
Head of Pancreas 
• Widest and thickest part of the gland 
• intimately  fit into the C loop of duodenum 
• Anterior–pylorus, transverse colon, mesocolon and anterior arcade of vessels                      
•Posterior –avasclar fasciae of Treitz separates from the retroperitoneal structures 
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Arterial supply 
Gatroduodenal and SMA form anterior& posterior arcades over the Head. 
Anterior & Posterior Pancreaticoduodenal arteries supplies head of pancreas 
and duodenum. This intimate blood supply is one reason for combined 
pancreaticoduodenal resection. 
 Anterior Arcade lies embedded  in the pancreatic substance and close to 
duodenum. 
 Posterior Arcade lies away from duodenum and outside the pancreas. 
 Inferior PD arteries may arise from1st jejuna branch, ligation of this may 
endanger DJ flexure. 
Anomalies which cause concern in pancreatic surgery are aberrant common 
hepatic from SMA, Acessory Rt. HAfrom SMA, Acessory Lt. HA from 
gastroduodenal or from Rt. Side of SMA. 
Venous Drainage 
Both arteries & veins lie posterior to duct and veins draining the pancreatic 
parenchyma eventually terminate into portal vein and its major tributaries. Small 
veins enter major veins laterally, this facilitates assessment by finger between neck 
and portal vein so also the dissection. 
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Lymphaticdrainage 
Rich  perilobular network draining into all direction posing challenge to  Oncological 
resection. Lymphatics drain to the nodes in the pancreatico Duodenal groove. These 
nodes are anterior and posterior pancreatico duodenal, superior and inferior head 
nodes, from these nodes, lymph drains to the portal, coeliac, mesenteric and para-
aortic nodes. 
Innervation 
Sympathetic post ganglionic fibers from the coelic ganglion serve as the principal  
pathways for  pain  of  pancreatic origin. Parasympathetic fibers from vagus serve as 
an exclusive efferent function. 
Structure and Histology 
Of the pancreatic mass, 80-90%  is composed of exocrine tissue, remaining is 
endocrine tissue. The pancreatic duct is lined by columnar epithelium from which 
most of the cancers arise. 
The mucosa of the ampulla of Vater is lined by columnar epithelium and is 
thrown into longitudinal folds likened to mucosal valvule 
Ampulla of Vater 
Papilla is present in the posteromedial wall of the second part of duodenum  
8 to10 cms distal to pylorus. In the papilla, there is the ampulla of Vater into which 
both pancreatic and common bileduct open. The ampulla of Vater is guarded by 
sphinter known as the Sphinter of Oddi, which regulates flow into the duodenum & 
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gallbladder filling, and resists reflux of duodenal contents. Proximal to the sphinter of 
oddi, distal common bile duct is guarded by sphincter choledochus known as Sphinter 
of Boyden and pancreatic duct is guarded by sphinter Pancreaticus. The oblique 
passage of the   wall and the presence of mucosal valvules may also help to prevent 
reflux.  
Common bileduct 
It is divided into supra duodenal, retroduodenal, infraduodenal and 
intraduodenal part. The infra duodenal part, that is the retropancreatic portion, runs in 
groove or tunnel in the pancreas, approaches the second part of duodenum obliquely 
accompanied by the terminal part of pancreatic duct. 
 Blood Supply of lower CBD - superior pancreaticoduodenal Artery 
 Venousdrainage –portalvein 
 Lymphaticdrainage–Lower hepaticnode, upper pancreatico splenic node 
 Nerve Supply – plexus over the superior pancreaticoduodenal Artery. 
Second part of the duodenum 
 7.5 cms in lengths, hugs the head of pancreas. 
 Supplied by superior and inferior pancreatico duodenal arteries. 
 Venous drainage – spleenic, Sup. Mesenteric and portal vein 
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SURGICAL PHYSIOLOGY 
In response to a meal, the pancreas secretes digestive enzymes in an alkaline 
(pH8.4) bicarbonate-rich fluid. Spontaneous secretion is minimal the hormone 
secretion, which is released from the duodenal mucosa, evokes bicarbonate-rich fluid. 
Cholecystokinin (CCK) is released from the duodenal mucosa in response to food: 
CCK produces no increase in the volume of secretion but is responsible for enzyme 
secretion. Vagal stimulation increases volume. Protein is synthesized at a greater 
rate(per gram of tissue)in the pancreas than in any other tissue, with the possible 
exception of the lactating mammary gland. About 90% of this protein is exported 
from the acinar cells as a variety of digestive enzymes. Approximately 6–20 g of 
digestive enzymes enters the duodenum each day. Nascent proteins are synthesized as 
preproteins, and during their transit through the rough endoplasmic reticulum Golgi 
cistranae the newly synthesized proteins undergo modification in a sequence of steps. 
The proteins move from the rough ER to Golgi complex, lysomes and mature 
zymogen storage granules containing proteases are stored, and move to the ductal 
surface of the cell, from which they are extruded by exostosis. During this phase, the 
proteolytic enzymes are in an inactive form, the maintenance of which is important in 
preventing pancreatitis. 
Bile, as it leaves the liver is composed of 97% water ,1–2% bile salts and1% 
pigments, cholesterol and fattyacids. The liver excretes bile at a rate estimated to be 
approximately 40ml/hr. The rate of bile secretion is controlled by cholecystokinin, 
which is released from the duodenal mucosa. With feeding there is increased 
production of bile. 
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PATHOLOGY 
Accurate histological classification of periampullary cancers can be 
notoriously difficult. Two practical points are useful in defining the orgin of these 
cancers,  the  predominent  site  of  mass,  the  presence  of  any  component  of 
carcinoma in situ. 
Periampullary  cancers  are  derived  from  their  respective  epithelia  and 
almost all are adenocarcinomas. Duodenal cancers can be classified morphologically 
as polypoid, flat  elevated and ulcerative-invasive; Ampullary and biliary cancers are 
classified as papillary, nodular and sclerosing types. Regardless of orgin, polypoid 
and papillary cancers have been associated with better prognosis. 
The degree of cancer cell differentiation varies widely among the 
periampullary cancers.  Undifferentiation (higher  histopathlogical grade),  is greatest 
for pancreatic cancers and least for ampullary cancers. 
Zhu and et al address similarities between duodenal and ampullary cancers. CEA in 
73% of duodenal and 63% of ampullary cancers, p53 in 20% duodenal and 13% 
ampullary cancers, c-neu in 60% duodenal and100% ampullary cancers. 
Longnecker and etal compared histologic findings between distal bileduct and 
pancreatic cancers. Desmoplasia was common in both cancers. And both had 
propensity for perineural invasion. Moreover, molecular and pathological features of 
oncogene and tumor suppresor genes 
15 
 
 
             Ebert and et al evaluated the presence of mutation on k-ras oncogene at 
codon12, which has been traditionally expressed in more than 80% of pancreatic 
cancers. Ampullary cancers have mutations at codon13. 
Friess and et al suggest a different molecular pathway in the development of 
ampullary and pancreatic cancers. The lack of upregulation of EGFR (epidermal 
growth factors) in ampullary cancers could partly account for their less aggressive 
behavior Markers of tumor biology in periampullary cancers suggest that genetic 
differences between these cancers probably contribute significantly toward 
phenotypic differences and the perceived clinical differences among periampullary 
cancers. 
Pathological examination of resected specimens showed that adenocarcinoma 
of head of pancreas was 40 to 60 % ampulla of Vater 20 to 40%, distal CBD10%, and 
duodenum 10% But, overall, the carcinoma of head of pancreas is the likely site of 
orgin upto 90% of cases. 
The majority of carcinoma of ampulla Vater, appear to be the intestinal type 
and show histological resemblance to colorectal adenocarcinoma. 
Cattell and Pyrtek first reported malignant transformation of an adenoma of papilla. 
In morethan 70% of investigated carcinomas of ampulla, tissue samples were found 
with severe dysplasia. At present there are substantial arguments, including molecular 
biological data, for hypothesis of an adenoma- dysplasia- carcinoma sequence of 
neoplastic lesion of ampulla. A villous adenoma of ampulla of Vater is considered as 
a premalignant lesion, with the consequence of complete extirpation of the  lesion  to 
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avoid development of cancer. The frequency of a malignant lesion in an adenoma of 
the papilla is around 26%. 
EPIDEMIOLOGIC CONSIDERATIONS 
INCIDENCE 
Overall Periampullary cancers account for 5% all GIT malignancies. 
Pancreatic cancer occurs most often among periampullary cancers. They account for 
3% of all GIT cancers. Ampulla of Vater represents less than 1% and adenocarcinoma 
of  duodenum  represents  about  0.5%  of  all  GIT  cancers. Carcinoma of ampulla of 
vater occur more frequently than distal CBD cancer with  a ratio of 1:12 
AGE 
The incidence of periampullary carcinoma increases steadily with increasing 
age, and over80 % of the patients seen in 6-8 decade of life.  
SEX  
The male to female ratio is usually reported as between 1.5 : 1 to 2 :1. 
PREVALENCE 
Surgeons should recognize the reports on operative result do not represents 
their actual incidents. Among resected Periampullary cancers, Ca. of head of Pancreas 
accounts for 50% to 70% Ampullary cancers for 15% to 25% Biliary cancers for 10% 
and duodenal cancers for  10%. These data reflect the prevalence of resected cancers. 
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Overall , perioperative mortality and morbidity for each cancers are similar, 0% to 
15% and 30% to 50% respectively. 
SURVIVAL 
Survival is greatest for ampullary and duodenal cancers and is intermediate for 
biliary cancers & least for pancreatic cancers. 
Although the perioperative outcome for these different cancers are similar, the 
long term survival has traditionally varied. It is unknown why outcome should vary 
for adenocarcinoma arising from different anatomic sites in such close proximity. 
ETIOLOGY 
ENVIRONMENTAL FACTORS 
1.  Cigarette Smoking 
This is only environmental factor that has been consistently associated with 
the pancreatic cancer. There is 2-3 fold increase in risk. The mechanism appears to be 
related to tobacco specific nitrosamines. 
Alternatively, smoking can elevate blood lipids which may also increase the 
risk of pancreatic cancers. There is a dose relationship to the number of cigarettes 
smoked and the occurrence of pancreatic cancer. Upto25% of pancreatic carcinoma is 
believed to be attributable to cigarette smoking. 
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2.  Diet 
A high intake of fat ,meat or both increase the risk by 1.5 times. Whereas the 
intake of fresh fruits and vegetables appears to have a protective effect. The diets high 
in fat stimulate cholecystokinin release which may induce pancreatic ductal 
hyperplasia and hypertrophy of acinar cells increased dietary protein associated with 
meat intake affect pancreatic enzyme out put. 
3.  Ethanol 
The evidence at the present time does not support the view that it is a risk 
factor. 
4. Coffee  
A case control study in Japan and a metanalysis of data published Between 
1981 and 1983 did not support the notion that either caffeinated or decaffeinated 
coffee or teas were risk factors for pancreatic cancer. 
5.  Toxic Substances 
Pancreatic cancer as well as bile duct cancer has been associated with 
occupational exposures to 2 –Naphthylamine and benzidine. 
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II. MEDICAL CONDITIONS 
1.  Pancreatitis 
Tropical and hereditary pancreatitis are associated with increased incidence of 
pancreatic cancer. A multicenter International study found that1.8 % of patients with 
chronic pancreatitis developed pancreatic cancer during a mean followup of 7.4 years. 
Occasionally a patient may present with acute pancreatitis as the first manifestation of 
carcinoma. 
2.  Partial Gastrectomy 
There is 5-7 times increased incidence of pancreatic cancer after15-20 years of 
partial gastrectomy. It may be related to increased production of nitrosamines. 
3.  Cholecystectomy  
Increased endogenus production of cholecystokinin can be seen in patients 
following this surgery, which has also been associated with increased risk of 
pancreatic carcinoma. 
4.        Diabetes Mellitus 
There is no consistent epidemiological association with diabetes mellitus and 
periampullary carcinoma. But this association appears to be the result of destruction 
of pancreatic tissues owing to the obstructing periampullary cancer and the resultant 
endocrine deficiency .Therefore ,as with chronic pancreatitis the development of 
diabetes in patients after 40 years of age should be considered a clue to the diagnosis 
of pancreatic cancer. 
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5.        Adenoma 
There is a hypothesis of adenoma-dysplasia carcinoma sequence of neoplastic 
lesions of ampulla. A villous adenoma of ampulla of Vater is considered as 
premalignant lesion, with the frequency of 26% malignant transformation. 
III. MOLECULAR GENETIC FACTORS 
There is a association of familial polyposis of the colon and Gardner’s 
syndrome with the periampullary carcinoma. In both conditions, adenomatous polyps 
of the duodenum or ampulla predispose to the development of carcinoma. The risk is 
200 times that of the normal population. 
There is association of hereditary pancreatitis, VonHippel–Lindau’s 
Syndrome, Lynch’s Syndrome II and ataxiatelangiectasis with pancreatic cancer. 
Molecular abnormalities includes a mutant C-Kirsten-eas(c-ki-ras) geneon 
codon 12 (upto 85%), and c-fos. Loss or a mutation of the p53 tumor suppressor Gene 
at the locus 17 p13 (50-70%)and over expression of EGF receptor are also associated 
with pancreatic cancer. 
CLINICAL PRESENTATION 
The early symptoms are usually vague and include anorexia, weight loss, 
abdominal discomfort and nausea. Specific symptoms develop only after invasion or 
obstruction of near by structure. 
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Jaundice: 
This is the specific symptom with which the patient presents. It is progressive 
in nature, and associated with pruritus which is due to irritation of cutaneous sensory  
nerves  by  retained  bile salts.  Pruritus relieved  by  bile  salt chelating resin-
cholestyramine suggests that bile salts are responsible for pruritus. 
Painless jaundice, infact, is found only in minority of patients. Most of the 
patients present with painful jaundice. Patient will pass yellowish urine due to 
increased excretion of bilirubin and clay coloured stools due to the absence of 
stercobilin. 
Pain: 
50-80% of presenting symptom of periampullary cancer abdominal pain is 
present less commonly in ampullary cancer than carcinoma Head. In majority of 
patients, pain of moderate intensity is present as a result of obstruction of either the 
biliary or the pancreatic duct. The more intense pain may be due to invasion of 
retropancreatic nerves as well as due to obstruction of the pancreatic duct. 
Weight loss 
In periampullary growth weight loss will be progressive. By the time the 
diagnosis is made, weight loss of more than 10 % of ideal body weight  is common. 
There are several possible explanations for the weight loss. Decreased intake of food 
is the commonest cause due to pain associated with anorexia. The other causes are 
malabsorption and increased catabolic activity. 
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Malena 
There may be malena due to bleeding from the tumor or due to infiltration of 
the duodenum, stomach, or colon. In some patients bleeding may be occult. Clay 
coloured stools are common and when mixed with blood it is called silvery or 
aluminium paint stool. 
Vomiting 
Nausea and vomiting due to duodenal obstruction, are usually late 
manifestations. 
Diabetes 
New onset diabetes is observed in 15 % to 20 % of patients with pancreatic 
cancer two years before diagnosis. 
Others 
Obstructions   of   pancreatic   duct   may   result   in   malabsorption and 
steatorrhea. An unexplained attack of pancreatitis in an older patient may be due to 
periampullary growth. The other less common manifestation is superficial 
thrombophlebitis. 
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PHYSICAL FINDINGS  
Gall bladder 
Although the gall bladder is frequently found distended at Laparotomy, it is 
palpated on clinical examination in  about 30 % - 50 % of patients with periampullary 
carcinoma. 
Courvoisier’s Law 
In obstruction of the common bile duct due to stone, distension of gallbladder 
seldom occurs the organ usually is already shriveled. In obstruction from other 
causes, distention is common by comparison. 
The reason for this difference between the two common causes of obstructive 
Jaundice is two fold .First in patients with calculous obstruction the gallbladder is 
commonly affected by cholecystitis with fibrosis and so it cannot readily  distend.  In 
patients  with  periampullary  carcinoma,  the  gallbladder  is usually normal and 
therefore it is distensible. 
Secondly in patients with stone in the duct the obstruction is usually 
incomplete so that the pressure in the ductal system does not rise as high as in 
malignant obstruction, where the obstruction is usually complete and continuous. 
Hepatomegaly 
It is palpable in about 50% of cases. It does not denote inoperability, since it 
may be due to biliary obstruction and not due to hepatic metastases. If there is a 
nodular liver with ascites, it indicates inoperability. Ascites is present in 25 % of 
cases. 
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Splenomegaly 
This is due to splenic vein thrombosis and occurs in about 10 % of cases. 
Inoperable signs 
Patient with peritoneal spread may present with palpable mass, ascites, 
umblical nodule, blumer shelf and Virchow’s Node (consequence of tumor cell 
arriving via thoracic duct) Few patients may present with pleural effusion, bone 
metastases. They indicate inoperability. 
INVESTIGATIONS 
Laboratory investigations 
I.  Urine examinations– To detect jaundice. 
1.  Macroscopic – colour – It will be yellow or dark yellow in colour. 
2.  Biochemical 
Bile salts, bile pigments – will be positive. Urobilinogen – will be negative. 
II. Stool examination 
1.  Macroscopic –colour- clay coloured due to absence of stercobilin. Sticky, 
tarry malena stools due to bleeding. 
2.  Occult blood – positive, if there is bleeding from periampullary growth. 
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III. Blood investigations. 
1.  Haemoglobin – may below. 
2.  Blood sugar – High if the patient is diabetic. 
3.  Blood urea and creatinine may be elevated due to renal impairment in 
obstructive jaundice. 
4.  Serum bilirubin–to confirm the hyperbilirubinemia. Normal – upto 1 
mg.At2mg,the tinge of jaundice appears, there will be conjugated 
hyperbilirubinemia. 
5.  Serum Alkaline phosphate (ALP) Normal Level–35 to 130IU/L. It will be 
elevated in the obstructive jaundice. 
6.  Serum Transaminases(ALT,AST).Normal Level–5 to 40 IU/L .Mild to 
moderate elevation is seen in the obstructive jaundice. 
7.  Prothrombin Time Normal–12 to16 seconds. It may be prolonged in the 
obstructive jaundice and correctable with administration of injection 
vitamin.K. 
8.  Serum proteins Normal–6.5to8gm%.They may be decreased and reversal of 
albumin – globulin ratio may be seen. 
DUODENOSCOPY 
This is the most useful investigation to  diagnose  the carcinoma  of  the 
ampulla of vater, with side viewing instrument, 
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1.        Growth can be seen in the ampulla. 
2.        Biopsy can be taken. 
3. Assessment of duodenal obstruction due to duodenal growth or infiltration of 
duodenum by carcinoma of head of pancreas. 
4.        ERCP-Endoscopic retrograde cholangio pancreaticography 
1)  Using the endoscopic approach ampullary and duodenal carcinoma can be  
visualized and biopsy can be taken. 
2)  If not able to take biopsy, with brushing of tumor, cytological examination can 
be made. 
3)  Abrupt tapering of both ducts (double duct sign) is highly suggestive of  
periampullary carcinoma. 
4)   A biliary stent can be placed through the obstructing lesion in the bile duct by 
 endoscopic approach to alleviate jaundice. 
5) We can accurately stage the tumor by doing endoscopic ultrasonography. 
RADIOLOGICALWORKUP.          
I.  BARIUM MEAL 
1. In carcinoma of the head of pancreas , it shows widening of the C-loop of the 
duodenum. It is called as ‘pad’ sign. 
2.       In carcinoma of the ampulla of vater, Reversed ‘3’ appearance can be seen. 
3.       Delayed gastric emptying and duodenal obstruction can be diagnosed. 
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Nowadays, barium meal is usually not done due to the advent of endoscopy 
and availability of other modalities of investigations like USG and CT scan. But if the 
patient is presenting with vomiting and OGD scopy showing no obstruction. We can 
still do Barium meal to detect delayed gastric emptying due to duodenal obstruction. 
II.  HYPOTONIC DUODENOGRAPHY. 
A double lumen tube (Gastroduodenal tube-scott Harden) is passed into the 
duodenum.20-40 ml of thin barium solution passed through it.4 mg of antrenyl was 
given intravenously to render the duodenum atonic, and air is insufflated. Then X-ray 
is taken. It gives a clear outline of the viscera. When carcinoma of head of pancreas 
has infiltrated the  duodenal  wall,  it  gives  the appearance of Spiculation of rose 
thorn. 
III. ULTRASONOGRAPHY 
a.  Transabdominal 
This is a painless, harmless ,non-invasive procedure which is relatively 
inexpensive and preferred investigation in jaundiced patients. It is widely available 
and entirely operator dependent with sensitivity of 80%-95%. 
The findings are intra and extra hepaticbiliary ductal dilatation, distended 
gallbladder, hypodense or isodense lesion in the head of pancreas, Secondary deposits 
in the parenchyma of liver and ascites. 
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b.  Endoscopic Ultrasonography (EUS) 
1)  It employs a 7.5–12MHZ transducer mounted on an endoscope to produce 
high resolution images. The pancreatic head and distal CBD are visualized 
from duodenum. 
2)  Recommended only for patients in whom pancreatic mass is suspected but 
can’t be confirmed by helical CT or ERCP. 
3)   Useful in detecting small pancreatic lesions(<2cm)and also lymphnode and 
vascular involvement. 
4)  Useful in evaluation of ampullary tumors with respect to invasion of duodenal 
wall, pancreas & vascular invasion & encasement. 
5)   Experience with this technique, which is operator-dependent is still limited, 
precluding its widespread use. 
6)  Normal pancreas is seen as having a homogenous echo patterns lightly 
brighter than that  of  the  liver.  The  features  of  the  carcinoma  pancreas  
are in homogenous and echo poor pattern, irregular outer margins, and the 
presence of tumorous pseudopodia. 
c.  Pancreatic duct Ultrasonography 
With  use  of  a  small  ultrasound  transducer  passed  through  the  biopsy 
channel of duodenoscope and into pancreatic duct, the duct was evaluated. It is useful 
to differentiate Chronic pancreatitis from pancreatic carcinoma. 
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IV.  CT SCAN 
Dynamic contrast enhanced spiral CT Scan detect lesion about 2cm in size. 
1.  It has an accuracy of 97% indetecting the presence of tumor. 
2.   The  CT  Criteria  of  unresectability  are local tumor extension  beyond  the 
confines of the normal gland, invasion of contiguous hollow or solid organs, 
circumferential or contiguous tumor involvement of major extra pancreatic 
arteries or/and veins, hepatic or lymph node metastases and ascites. 
3. Although, CT Scanning is a specific modiality for determination of 
unresectability for pancreatic carcinoma. It does not accurately identify 
patients with resectable lesion. 
4.  In approximately 40% of cases, CT Scan evaluation alone under estimates the 
extent of lesion. 
V.  MRI 
Ultra fast MR imaging, including MR cholangiopancreatography, 
angiography, MR with Echoplanner imaging, may replace ERCP, in near future. 
VI.  Laparoscopy 
This is an additional staging modality to evaluate periampullary patients 
before they are subjected to laparotomy. 
1)  Can pick up small liver or peritoneal metastases, which are usually missed by 
CT Scan. 
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2)  Irrigation of peritoneal cavity can be performed and washings analysed 
cytologically for evidence of shed malignant cells. 
3)  Palliative Stent can be placed in inoperable cases, as a therapeutic measure. 
4)  Laparoscopy contact USG is the newer diagnostic method used to decide the 
diagnostic dilemma cases for surgery. 
5)  Combination of dynamic CT and Laparoscopic staging has an accuracy of 
>90% in predicting resectability. 
VII. Biopsy and FNCA 
Diagnosis is confirmed by taking biopsy from the periampullary growth via an 
endoscope. In a palpable mass, we can do CT or EUS guided FNAC. But FNAC is 
not used for potentially resectable tumors, because negative result does not rule out 
carcinoma and the fear of shedding of tumor, either along the needle tract or into the 
peritoneal cavity. 
For resectable lesion, Preoperative FNAC is of no additional value except 
when preoperative neoadjuvant chemo or radiation is contemplated. 
For irresectable cases, percutaneous FNAC has a role in proving diagnosis 
before consideration of Palliative chemo RT. 
VIII. Estimation of CA–19-9. 
• Normal Value < 35 U/ml 
• In Pancreatic Cancer > 100 U/L (in 73% of patients) 
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It has a sensitivity and specificity approaching 90% for tumors arising in the 
pancreas. It is useful for prognosis and follow up surveillance. 
IX.  Angiography 
Preoperative visceral angiography with arterial injection of celiac & SMA 
with venous phase studies provides the best demonstration of vascular anatomy, 
major vessel encasement or occlusion. It will also detect anatomical variations, such 
as a replaced right hepatic artery or Atherosclerotic stenosis or celiac axis. 
PREOPERATIVE STAGING 
Preoperative staging is more useful for pancreatic tumors than for other forms 
of periampullary cancer, since resectability for the latter lesions is usually 
significantly higher at the time of presentation than it is for pancreatic cancer. In 
many patients, dynamic spiral CT with oral and intravenous contrast will provide all 
the information necessary by demonstrating liver metastases or major vascular 
invasion. 
Preoperative visceral angiography with arterial injection of the celiac and 
superior mesenteric arteries with venous phase studies provides the best 
demonstration of vascular anatomy and major vessel encasement or occlusion. 
Visceral angiography  also  will  detect  anatomic  variations,  such  as  a 
replaced right hepatic artery or atherosclerotic stenosis or occlusion of the celiac axis 
that may alter operative management. Angiography is indicated, however, in these 
patients to rule out involvement of the superior mesenteric and portal vein and/or 
celiac axis. 
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Endoscopic ultrasonography is to detect small pancreatic lesions (<2 cm) 
and also lymph node and vascular involvement. This technique is also particularly 
useful in the evaluation of ampullary tumors with respect to invasion of the duodenal 
wall and pancreas. 
A recent study in preoperative patients  suggested  that  endoscopic ultrasound 
examination was superior to conventional sonography. 
Liver metastases and peritoneal implants are the common sites of spread of 
periampullary carcinoma. Once distant metastasis present, survival is so limited that a 
conservative approach is indicated. 
The technique of diagnostic laproscopy, before the patient is subjected to 
laparotomy, has been used by several groups as an additional staging modality for the 
evaluation of patients with pancreatic and periampullary malignancies. 
TREATMENT OF PERIAMPULLARY CARCINOMA 
Treatment of periampullary carcinoma depends upon the stage at presentation 
and presence or absence of comorbid medical conditions influencing treatment 
modalities. 
Surgical resection of the tumor currently provides the only opportunity for 
cure in these patients if the tumor is resectable. 
If the patient is presents with unresectable tumor with jaundice, with or 
without hepatic secondaries, we can do palliative biliary enteric and Gastro jejunal 
anastomosis, if there is no other comorbid medical diseases contraindicating the 
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surgery. If the patient is medically unfit for surgery an endoscopic stenting may be 
done. 
A patient with wide spread metastatic disease, does not need any type of 
surgery because median survival is short. In these patients, palliative endoscopic 
biliary stenting can be done to relieve the jaundice. If the patient has unresectable 
tumor with severe pain, celiac axis block, either percutaneously or during laparotomy, 
can be done. 
PREOPERATIVE PREPARATION 
If the surgery is planned, whether it is curative or palliative, it is important to 
optimize cardiac, pulmonary and renal function preoperatively, as in all patients about 
to undergo major surgery. 
Because obstructive jaundice can cause defects in hepatic and renal function, 
it is important to correct all these abnormalities preoperatively if they are present. 
1. Correction of anemia with preoperative blood transfusion. 
2.  All patients are adequately nourished with high allowance of carbohydrate 
diet. 
3.  If there is dehydration due to vomiting in patients with duodenal obstruction, 
It is corrected by administration of intravenous fluids. 
4.  If there is duodenal obstruction, stomach wash should be given with normal 
saline. 
5. Correction of disorders of coagulation 
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The coagulation defect encountered in patients with obstructive jaundice is 
prolonged prothrombin time, resulting from deficiency of Vitamin K dependent 
clotting factors due to malabsorption of this vitamin. 
It is corrected by administration of intramuscular injection of phytomenadione 
(VitK) for 1-3 days or with blood and fresh frozen plasma transfusion. 
6. Prevention of renal failure 
Septicemia and liver damage perse are associated with adverse effects on renal  
structure and function, and on circulatory haemostasis and on the integrity of the 
gastrointestinal  barrier.  Even  in  the  absence  of  infection,  endotoxemia  is 
frequently present in jaundiced patient where it results from the absorption of 
endotoxin produced by the intestinal microflora. Therefore, the patients with 
obstructive jaundice have an increased risk of Postoperative acute renal failure. 
 Two  pints of  10%  Dextrose  infusion  given  every  day  prior  to surgery 
minimum for 3 days. 
 Mannitol may be given on the day before, during and the day after surgery. 
It protects the kidneys by acting as an osmotic diuretic and by increasing the 
renal perfusion. 
 Oral Lactulose to reduce the intestinal absorption of endotoxins from the 
Intestinal microflora. 
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All patients undergoing surgery should be catheterized and the urint output 
measured hourly. Further administration of diuretic is indicated if the urine output 
falls consistentlybelow40ml/hr. 
WHIPPLE’S  PANCREATICODUODENECTOMY 
Step 1 
•  uppermidline/subcostal  incision . 
•  inspect liver & peritoneal surfaces. Biopsy /frozen section of suspected area 
• regional nodes are inspected (periaortic lympnodes of the celiac axis indicates 
tumor is beyond the limits of resection) 
•  once  distant metastsis  are ruled out, assess  local resectability. 
• positive nodes within the planned field of resection are not considered a 
contraindication to curative surgery. 
Step 2 
The  hepatic  flexure  of  colon  is mobilized  from  its  retroperitoneal 
attachment ,giving access to the 3&4 portions of the duodenum. Extensive 
mobilization of right colon &small bowel mesentry (Cattell-Braasch maneuver) is 
unnecessary except for lesions involving the fourth portion of duodenum, or for the 
approach to mobilization and resection of segment of SMV. The duodenum and head 
of pancreas are separated from the retroperitoneal bed medially past aorta and distally 
to the ligament of Treitz. 
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EXPOSUREOF THE ABDOMINAL CAVITY 
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The gallblader is removed and the bileduct is dissected free from adjacent 
portal structures and divided above the entry to cystic duct across the common 
hepaticduct (because of tendency of periampullary cancers to infiltrate cephlad along 
the submucosal lymphatic channels of bile duct). 
The distal bile duct orifice is sutured to minimize spillage of tumor cells, but 
no clamp is used on the proximal bile duct, to avoid trauma to the duct. If evidence of 
unresectable cancer is discovered later in the operation, the proxial duct is used for 
palliative bypass. The tissues lateral toportal vein are carefully separated and divided, 
with additional care taken to be sure that are placed aberrant right hepatic artery of the 
SMA is not included. 
Step 4 
The portal dissection is continued down along the anterior aspect of the portal vein, 
beginning with development of the tunnel in front of the vein and behind the neck of 
pancreas. Division of right gastric artery & gastroduodenal artery enlarges this 
window. Division of these vessels facilitates dissection of portal vein behind 
pancreas. The middle colic vein and gastroepiploic vein can be traced down to SMV 
for rapid identification.(Periampullary tumors are much more likely to involve the 
lateral & posterior aspect of portal /mesenteric vein) 
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Step 5 
After dividing the left gastric & gastroepiploic vessels at the gastric wall, the 
stomach is divided across the proximal antrum. Alternatively, the Duodenum 2 cm 
past the pylorus may be divided 
Step 6 
After the pancreatic neck has been carefully dissected from anterior surface of 
portal-superior mesenteric vein, a penrose drain is placed behind the neck to elevate 
and protect the portal vein during division. Four hemostatic sutures are placed on 
either side of the transection line. The pancreas is now ready to be divided with 
electrocautery. 
Step 7 
Ligament of Treitz is taken down in its entry and the jejunum is divided 6 to10 
cm past the ligament. The jejuna vascular branches are divided at the bowel wall 
along the inner curvature. 
Step 8 
The final step in removal of the specimen is to divide the venous tributaries of 
SMPV and dissect along the lateral margin of the SMA, taking both arterial branches 
& the periarterial soft tissues, which include both Lymphatics& nerve plexuses that 
can contain tumor. 
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GASTRO-JEJUNOSTOMY IN PROGRESS 
 
 
 
 
 
CHOLEDOCHO-JEJUNOSTOMY IN PROGRESS
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Step 9 
Pancreaticojejunostomy is performed first. The anastomosis is created in two 
layers, end-to-side, duct-to-mucosa, using an outer row of interrupted, non-absorbable  
3-0  sutures that includes most of the cut surfaces of pancreas & an inner row of 4-0 
interrupted synthetic  absorbable sutures duct- to  –mucosa. When the pancreatic duct 
is small or normal in size a 5F feeding tube is placed in the pancreatic duct and 
brought out through the jejunum. 
Step 10 
10 cms distal to the pancreatic anastamosis, an end –to- side hepatico 
jejunostomy is made with a single layer of interrupted closely spaced synthetic 
absorbable sutures. A small (8 to 12 F) catheter can be left through  the anastamosis& 
brought out distally through jejunum. 
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PANCREATICO-JEJUNOSTOMY IN PROGRESS 
 
 
 
 
SPECIMEN 
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Step 11 
After fixing the jejuna loop to the transverse mesocolon with interrupted non 
absorbable sutures, GI continuity is restored with aretro-colic Hofmeister-type 
Billroth II gastrojejunostomy. This anastamosis is made with running absorbable 
sutures as an inner layer and interrupted nonabsorbable sutures as an outer layer.  
Step 12 
Soft closed-suction drains are placed in the right upper quadrant, anterior and 
posterior to biliary and pancreatic anastamoses. These are brought out through 
separate incisions in the right side of the abdomen. The abdominal wall is closed in 
layers. 
POST OPERATIVE CARE 
The  nasogastric  tube  is  discontinued  on  postoperative  day  1  and  clear 
liquids may be allowed on day 2. The diet is advanced to low-fat softsolids in 
frequent small feedings as tolerated. Blood glucose should be monitored and diabetes 
treated as appropriate. The concentration of amylase with closed- suction drainageis 
measured on day5 or 6 when the patient is eating. If there are no indications of an 
anastomotic leak, the drains are removed on the sixth and seventh days. The 
pancreatic (and biliary)stents are removed at the post-operative visit, generally at 2 to 
3 weeks. 
Pancreatic leak / fistula remain the most common serious complication of this 
operation. The mainstay of treatment is complete drainage of pancreatic leaks, either 
by closed-suction drains placed at operation or by percutaneously placed catheters if 
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leak appears is delayed. The catheters should be left in place long enough to ensure 
formation of a secure tract and then withdrawn in segments to allow the tract to close 
behind as drainage closes. In the case of low-volume fistulas (less than 200 ml per 
day), patients may eat and be discharged to home. High output fistulas may require a 
more aggressive approach with fasting, maintenance of fluid and electrolyte balance, 
and parenteral nutrition. Octreotide 200 units subcutaneously three times a day has 
been used as an adjunct to reduce fistula volume, but there is no clear evidence that 
closure is accelerated. 
In the event of delayed gastric emptying for more than 7to 10days ,a 
gastrografin contrast upper GI  study should be performed to ruleout mechanical 
obstruction. In most cases the condition resolves spontaneously, although the 
gastroparesis can persist as long as 3 to4 weeks. Management consists of support. 
PALLIATION OF OBSTRUCTIVE JAUNDICE- 
Options for establishing biliary decompression are divided into endoscopic, 
radiologic and surgical approaches. Patients  with  histologically  proven unresectable 
disease are most commonly treated by endoscopic or radiologic biliary stent 
placement. The sequence of palliative intervention is determined by the method used 
for cancer staging: laparotomy versus laparoscopy. 
For patients undergoing laparotomy, surgical bypass is a reasonable option in 
the presence of obstructive jaundice and the feasibility of the procedure should be 
guided by the findings at surgery prophylactic bypass in these patients is controversial 
but should be tailored to an individual patient’s needs. 
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For patients undergoing laparoscopy, biliary decompression endoscopic stent 
placement is recommended if not successful or unavailable, then the radiologic PTH 
stent placement should be performed to avoid laparotomy. 
In patients who develop recurrent obstructive jaundice following failure of the 
initial stent or because of progressive tumor radiologic PTH placement of expandable 
metallic wall stents under imaging control may then be indicated. 
Palliation of gastric outlet obstruction 
The management of pancreatic cancer patients with the potential to develop 
gastric outlet obstruction (reportedly3% - 9%) is predicated on the initial surgical 
staging technique (laparotomy versus laparoscopy). 
Patients with equivocal or potentially resectable disease, who undergo 
laparotomy, can be assessed for duodenal involvement or impending obstruction from 
the tumor during the surgery. Guided by the operative assessment, gastrojejunostomy 
can be performed effectively. Routine prophylactic gastric bypass in staging 
laparotomy has been historically advocated however, the need for the procedure 
should be based on the individual patient’s needs. Patients with histologically 
confirmed unresectable disease and those undergoing  staging  laparoscopy  rather   
than  laparotomy  for   equivocal   or potentially resectable pancreatic cancer are 
reasonably managed without prophylactic gastric bypass. If the patient develops 
subsequent obstruction, then gastric decompression can be achieved by several 
different methods, guided by the individual patient’s condition. 
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Patients with good performance status, who are expected to have an extended 
survival, should undergo gastric bypass, preferably laparoscopically or by  
laparotomy.  For  patients  developing gastric  outlet  obstruction  as  a  near- terminal 
event, the endoscopic gastrostomy tube or expandable duodenal stent placement 
should be considered. 
Palliation of pain 
Standard   narcotic   analgesics   are   inadequate   for   most   patients   with 
pancreatic malignancy. Percutaneous celiac blockade for patients with histologically 
proven unresectable disease, who do not undergo laparotomy, is a logical approach 
(those undergoing laparotomy should be considered for intraoperative celiac 
blockade).Patients who obtain only short-term analgesia or fail to achieve pain relief 
from the percutaneous or laparotomy approaches should be considered on an 
individual basis for video-assisted thoracoscopic nerve transection. 
NEOADJUVANT ANDADJUVANT THERAPY 
Adjuvant chemoradiation therapy generally comprises external beam radiation 
therapy. 
The theoretical advantages of neoadjuvant chemotherapy for patients with 
resectable pancreatic cancer are (1)it may be more effective to give radiation in well- 
vascularized tissues. (2) Previously unresectable tumors may become resectable, and 
(3) it may improve patient selection, preventing unnecessary laparotomies in patients 
with evidence of disease progression on neoadjuvant therapy (which occurs in 
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approximately 20% of patients). Despite these theoretic advantages, however, 
neoadjuvant therapy has not been shown to be superior to adjuvant therapy. 
Adjuvant intra operative electron beam radiation therapy(IORT),which 
delivers a single dose of 10 to 20 grays to the tumor bed at the time of resection, has 
therefore been used, alone or in combination with standard chemoradiation protocols 
to improve local control. In patients receiving neoadjuvant or adjuvant hemoradiation, 
tumor recurrence patterns change from locoregional failures  to systemic failures, 
with liver metastases becoming the predominant site of metastasis. 
Thus more effective systemic agents are needed. One such potential agent is 
gemcitabine(2’ – deoxy-2’2’-difluorocytidine,  Gemzar), a  deoxycytidine analog 
capable of inhibiting DNA replication and repair. Gemcitabine is also a potent 
radiation sensitizer and is being combined with EBRT using a variety of treatment 
schedules in patients with advanced pancreatic cancer. 
PREDICTORS OF SURVIVAL AMONG PERIAMPULLARY   CANCERS 
Early vs Late Jaundice 
Patients with cancers directly involving the distal bile duct should present with 
jaundice at an earlier stage of disease. Current data suggest that most ampullary, 
duodenal, and distal bile duct tumors present without lymph node metastases, and 
consequently when resected are associated with a better prognosis than pancreatic 
cancer. Although bile duct cancers should present early and should be associated with 
a prognosis equivalent to ampullary cancers, the fact that survival is not equivalent 
suggests that other tumor subtype factors are involved. Clearly, the T stage of 
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pancreatic cancer that obstructs the bile duct by extension from the pancreatic duct 
with encase mentor invasion must be more advanced than the other periampullary 
cancers. 
Factors 
Focal growth  patterns  of  the   primary  periampullary cancers  likely 
contribute to outcome. Although initially all periampullary cancers arise 
intraluminally from mucosa, subsequent invasion of duct or gut wall carries different 
implications. 
Intraluminal Growth 
Biologic behavior among periampullary cancers is also manifested in their 
direction of growth. Intraluminal growth is present in 40% of ampullary cancers but 
in only 2% of pancreatic cancers and is followed by extraductal invasion in 60% of 
the ampullary cancers and 98% of the pancreatic cancers. Adjacent tissue invasion 
represents advanced T stage of disease and therefore a poorer prognosis with an 
increased rate of invasion of lymphatic, venous, and perineural structures. 
When an non pancreatic periampullary cancer invades the pancreatic parenchyma, the 
prognosis worsens (similar to the pancreatic counterpart),and the frequency of 
lymphatic involvement increases significantly. Invasion of ampullary cancers into the 
duodenal wall does not have the same adverse impact as does pancreatic invasion. 
Clearly, pancreatic invasion or origin port ends a poor prognosis. Similar findings for 
the relationship of T stage for duodenal cancers and prognosis have been reported. 
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Lymphatic and Neural Spread 
Lymphatic Spread. Lymphatic metastases represent an advanced disease 
stage. In fact, some authors maintain that lymphatic invasion is equivalent to 
established lymphatic metastases. Pancreatic cancers present with lymph node 
metastases in 56% to 79% of patients, ampullary cancers are associated with 
lymphatic metastases in 30%  to 50%, and bile duct cancers in 56% to 69%. The 
frequency of lymph node metastases is significantly increased when non pancreatic 
periampullary cancers invade the pancreas, which is especially reflected in para- 
aortic lymph node metastases. 
Ampullary tumors often have limited nodal involvement. These cancers 
usually involve the posterior pancreatoduodenal nodes (“first echelon”)  and seldom 
the nodes located to the left of the superior mesenteric artery and the celiac ganglion. 
In contrast, the nodal involvement in pancreatic cancer is more extensive and clearly 
involves both the above nodal groups. Shirai et al showed an increased survival after  
pancreatico duodenectomy and  radical  lymphadenectomy  in ampullary tumors, 
which supports further evaluation of this aggressive approach even in the presence of 
lymphatic spread. 
Duodenal tumors behave biologically differently than pancreatic cancers. 
There is 36% to 47% incidence of positive lymph nodes in pancreaticoduodenectomy 
specimens. Despite this frequency of nodal involvement, however ,5-year survival 
rate approaches 40%to50%. In contrast, the presence of positive lymph nodes in 
patients with pancreatic cancer is associated with a 5-year survival of only5% These 
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findings justify a role for aggressive resection in duodenal and ampullary cancers, 
even in the presence of positive lymph nodes. 
Perineural Invasion. Perineural invasion, especially extrapancreatically, is an 
important prognostic factor associated with pancreato biliary tract cancer and 
generally denotes a poor prognosis. Most patients with pancreatic carcinoma have 
perineural invasion (concomitantly with lymphatic vessel invasion).This feature of 
pancreatic cancer may contribute to the high incidence of local recurrence, especially 
retroperitoneally. In contrast, perineural invasion occurs in only 5% to 17% of 
patients with ampullary cancers, which has a lower local recurrence rate after 
resection. Interestingly, when perineural invasion is present with periampullary 
cancers, the prognosis is similar to pancreatic cancers. Finally, although  bile  duct  
cancers  are  associated  with  a  high  (86%)  incidence  of perineural invasion, 
correlation with local recurrence has not been established because the frequency of 
positive post-resection margins is a confounding factor. 
Molecular Concepts and Clinical Correlation Duodenal and ampullary tumors 
have the best prognosis among periampullary cancers. They are similar in their 
genesis; some ampullary cancers may arise from the duodenal type of epithelium and 
hence they share some of the steps of the molecular development model. This fact is 
evidenced in the data by Zhu et al, where some genes, tumor markers, and  expression 
of growth factors are present in similar percentage in both cancers.  Other genetic 
alterations, like the mutation of the K-ras oncogene, are almost Exclusive to 
pancreatic cancers among the periampullary cancers. Pancreatic Cancers also express 
the receptor for EGFR, which is not expressed by other Periampullary cancers and is 
associated with a much worse prognosis. Finally, some histologic similarities were 
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found between bile duct and pancreatic cancers, traditionally the ones with the worst 
outcome. Overall, it is impossible to point out a specific factor to explain the different 
outcomes of these cancers. The combinations of these features will ultimately 
determine the biologic behavior of each cancer. 
Stage at Initial Presentation. Size of primary tumor, tumor histologic 
differentiation, lymph node status, and resection margin status are very important 
when defining poor prognostic factors. At presentation, pancreatic cancers have the 
highest frequency of these factors when compared with non pancreatic periampullary 
cancers. A higher incidence of positive margins after apparent curative resection in 
pancreatic cancer is a reflection of its usual early perineural invasion and accounts for  
its  higher  locoregional  recurrence.  The  clinical  correlation  of  decreased 
survivalin pancreatic cancer is obvious after analysing the data. 
INNOVATIVE STRATEGIES 
Significant advances in understanding basic immunology have renewed 
interest in using immunotherapy to treat pancreatic cancer. Cancer immunotherapy, 
including humanized Monoclonal Antibodies, cytokines, and potent vaccine 
strategies, has been successful in animal models and is being evaluated in clinical 
trials. 
Gene therapy is also being explored using methods to inactivate oncogenes, 
replaced effective tumor suppressor genes, enhanced chemosensitivity to tumor cells, 
and increase immunogenicity of tumor cells. 
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Angiogenesis, an essential step in the growth and metastasis of pancreatic 
cancer, has been targeted by many antiangiogenic agents. Several clinical trials have 
been initiated to evaluate the role of these innovative strategies in patients with 
pancreatic cancer with increasingly sophisticated correlative studies to learn more 
about the mechanisms of tumor rejection with these agents. The rapid translation of 
basic science discoveries to clinical trials should result in the development of new 
effective treatments for patients with pancreatic cancer. 
KEYPOINTS 
Most of the Literatures support the clinical impression that periampullary 
cancers vary in outcome after resection. 
Overall survival after pancreaticoduodenectomy is greatest for patients with 
ampullary and duodenal cancers, intermediate for patients with bileductcancer, and 
least for patients with pancreatic cancer. 
Moreover, survival for each tumor stage is greater for non pancreatic 
periampullary cancers than for pancreatic cancers. Invasion of the pancreas by non 
pancreatic periampullary cancers is a major factor adversely affecting survival. 
Recent data suggest that inherent differences in tumor biology rather than 
embryologic,  anatomic,  or  histologic  factors  probably  account   for  these 
differences in survival. 
Finally,  although  pancreaticoduodenectomy  remains  the  procedure  of 
choice  for  resectable periampullary  cancers,  further  increases in  survival  will 
likely evolve through more effective neoadjuvant or adjuvant therapies rather than 
modification in the surgical approach. 
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MATERIALS AND METHODS 
This work includes the study of 25 patients, with a diagnosis of periampullary 
carcinoma, who were admitted in the Stanley Medical College Hospital, Chennai, 
between FEB 2016 to SEP 2016. 
The methods include obtaining the important informations from  the patients, 
thorough clinical examination and doing the investigations whatever necessary to aid 
the diagnosis and resectability. All the informations were entered in a proforma 
specially designed for this study. 
The patient’s age, sex, symptoms and its duration were obtained. Personal 
history like smoking habits, alcohol consumption and their duration were noted. 
History of recent onset of diabetes mellitus, if present was noted. 
In all these patients, nourishment and presence of jaundice were noted. 
Abdomen was examined to detect hepatomegaly, palpable gallbladder, ascites and 
mass. Rectal examination was done to find out rectovesical or rectovaginal deposits. 
Respiratory system was examined to find out the pleural effusion. 
Enlargement of left supra clavicular node (virchow‘snode) and umbilical nodule 
(sister mary joseph’s nodule) if present, were  noted. Basic investigations like urine 
examination, Hb% estimation, Blood sugar and renal parameters like urea and 
creatinine were done in all these patients. liver function test like serum bilirubin, 
serumproteins, clotting time, serum alkaline phosphatase, liver enzymes and 
prothrombin time were also done. 
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Upper gastrointestinal endoscopy was done in all the patients and biopsy was 
taken if the growth was seen. 
Initially, ultrasonogram abdomen was done in all patients, then CT Scan 
abdomen was done to confirm the diagnosis and to know the resectability. X-ray chest 
was taken to know the pulmonary metastases and pleural effusion. 
Based on above investigations treatment was planned accordingly. If the 
patient was fit for surgery, either curative resection or palliative bypass procedure was 
done. If not, the patient was managed conservatively or referred to higher institutions 
for palliative endoscopic stenting. 
Postoperative complications were noted and managed accordingly. Most of 
the patients who were operated were followed up in our review clinic. 
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AGE  
 
 
  
 
AGE RANGE 
  
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 30 - 40 yrs 5 20.0 20.0 20.0 
41 - 50 yrs 5 20.0 20.0 40.0 
51 - 60 yrs 10 40.0 40.0 80.0 
61 - 70 yrs 5 20.0 20.0 100.0 
Total 25 100.0 100.0  
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GENDER 
 
 
 
 
 
 
SEX 
  
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Female 8 32.0 32.0 32.0 
Male 17 68.0 68.0 100.0 
Total 25 100.0 100.0   
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LOCATION OF LESION 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid AMPULLARY 11 44.0 44.0 44.0 
DISTAL CBD 4 16.0 16.0 60.0 
DUODENUM 
D2 
4 16.0 16.0 76.0 
HEAD OF 
PANCREAS 
6 24.0 24.0 100.0 
Total 25 100.0 100.0   
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AGE RANGE WITH GENDER 
 
 
 
 
 
 
 
 
CROSSTAB 
  
SEX 
Total F M 
Agerange 30 - 40 yrs Count 2 3 5 
% within 
SEX 
25.0% 17.6% 20.0% 
41 - 50 yrs Count 2 3 5 
% within 
SEX 
25.0% 17.6% 20.0% 
51 - 60 yrs Count 3 7 10 
% within 
SEX 
37.5% 41.2% 40.0% 
61 - 70 yrs Count 1 4 5 
% within 
SEX 
12.5% 23.5% 20.0% 
Total Count 8 17 25 
% within 
SEX 
100.0% 100.0% 100.0% 
 
 
 
 
 
0
2
4
6
8
30 - 40 yrs 41 - 50 yrs 51 - 60 yrs 61 - 70 yrs
2 2 
3 
1 
3 3 
7 
4 
Age range with gender 
Female Male
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Crosstab 
  
SEX 
Total F M 
LOCATION 
OF LESION 
AMPULLARY Count 3 8 11 
% within 
SEX 
37.5% 47.1% 44.0% 
DISTAL CBD Count 1 3 4 
% within 
SEX 
12.5% 17.6% 16.0% 
DUODENUM 
D2 
Count 2 2 4 
% within 
SEX 
25.0% 11.8% 16.0% 
HEAD OF 
PANCREAS 
Count 2 4 6 
% within 
SEX 
25.0% 23.5% 24.0% 
Total Count 8 17 25 
% within 
SEX 
100.0% 100.0% 100.0% 
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Female Male 
AMPULLARY 3 8 
DISTAL CBD 1 3 
DUODENUM D2 2 2 
HEAD OF PANCREAS 2 4 
 
 
 
 
BILIRUBIN 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid INCREASED 19 76.0 76.0 76.0 
NORMAL 6 24.0 24.0 100.0 
Total 25 100.0 100.0   
 
 
Chi-Square Tests 
  Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 12.664a 3 .005 
Likelihood Ratio 14.738 3 .002 
N of Valid Cases 25     
a. 7 cells (87.5%) have expected count less than  
5. The minimum expected count is .96. 
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 ALBUMIN 
DECREASED NORMAL 
LOCATION OF 
LESION 
AMPULLARY                  Count 
% within ALBUMIN 
10 
52.6% 
1 
16.7% 
DISTAL CBD                   Count 
% within ALBUMIN 
3 
15.8% 
1 
16.7% 
DUODENUMD2             Count 
% within ALBUMIN 
2 
10.5% 
2 
33.3% 
HEAD OF PANCREAS   Count 
% within ALBUMIN 
4 
21.1% 
2 
33.3% 
Total                                                                           Count 
% withinALBUMIN 
19 
100.0% 
6 
100.0% 
 
 
Chi-Square Tests 
  Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 3.112a 3 .375 
Likelihood Ratio 3.170 3 .366 
N of Valid Cases 25     
a. 7 cells (87.5%) have expected count less than 5. The minimum 
expected count is .96. 
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PREVIOUS SURGERY 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid   NO                           
YES                
Total     
 
 
22 
3 
25 
88.0 
12.0 
100.0 
88.0 
12.0 
100.0 
88.0 
100.0 
 
ERCPSTENTED 
   
Valid Frequency Percent Valid Percent 
Cumulative 
Percent 
NO                               
YES 
Total 
16 
9 
25 
64.0 
36.0 
100.0 
64.0 
36.0 
100.0 
64.0 
100.0 
 
IONOTROPIC SUPPORT 
 
Valid Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
NO           
YES 
Total 
12 
13 
25 
48.0 
52.0 
100.0 
48.0 
52.0 
100.0 
48.0 
100.0 
 
SEPSIS 
Valid Frequency Percent Valid Percent 
Cumulative 
Percent 
ABSENT         
PRESENT 
Total 
14 
11 
25 
56.0 
44.0 
100.0 
56.0 
44.0 
100.0 
56.0 
100.0 
 
BIOCHEMICALDERANGEMENTS 
Valid Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
ABSENT 
PRESENT 
Total 
8 
17 
25 
32.0 
68.0 
100.0 
32.0 
68.0 
100.0 
32.0 
100.0 
 
RELAPOROTOMY 
Valid Frequency Percent Valid Percent 
Cumulative 
Percent 
NO                   
YES 
Total 
20 
5 
25 
80.0 
20.0 
100.0 
80.0 
20.0 
100.0 
80.0 
100.0 
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LOCATION OF LESION*ERCP STENTED 
 
CASE PROCESSING SUMMARY 
 
 Cases 
Vali
d 
Missing Tota
l N Percent N Percent N Percent 
LOCATIONOF 
LESION * ERCP 
STENTED 
LOCATIONOF 
LESION * PREVIOUS 
SURGERY 
25 
 
 
25 
100.0% 
 
 
100.0% 
0 
 
 
0 
0.0% 
 
 
0.0% 
25 
 
 
25 
100.0% 
 
 
100.0% 
 
  
ERCP STENTED 
Total NO YES 
LOCATION 
OF LESION 
AMPULLARY Count 5 6 11 
% within 
ERCP 
STENTED 
31.3% 66.7% 44.0% 
DISTAL CBD Count 2 2 4 
% within 
ERCP 
STENTED 
12.5% 22.2% 16.0% 
DUODENUM D2 Count 4 0 4 
% within 
ERCP 
STENTED 
25.0% 0.0% 16.0% 
HEAD OF 
PANCREAS 
Count 5 1 6 
% within 
ERCP 
STENTED 
31.3% 11.1% 24.0% 
Total Count 16 9 25 
% within 
ERCP 
STENTED 
100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS  
 
  
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 5.206a 3 .157 
Likelihood Ratio 6.561 3 .087 
N of Valid Cases 25     
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 PREVIOUS SURGERY 
NO YES 
LOCATION 
OF LESION 
AMPULLARY                  Count 
% withinPREVIOUS SURGERY 
11  
50.0% 
0 
0.0% 
DISTAL CBD                   Count 
% withinPREVIOUS SURGERY 
4 
18.2% 
0 
0.0% 
DUODENUMD2             Count 
% withinPREVIOUS SURGERY 
3 
13.6% 
1 
33.3% 
HEAD OF PANCREAS   Count 
% withinPREVIOUS SURGERY 
4 
18.2% 
2 
66.7% 
Total                                                                           
Count 
% within PREVIOUS SURGERY 
22 
100.0% 
3 
100.0% 
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CHI-SQUARETESTS 
 
  
Value 
 
df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 
Likelihood Ratio 
N of Valid Cases 
5.271a 
6.209 
25 
3 
3 
.153 
.102 
 
a.6 cells (75.0%) have expected count less than 5. The minimumexpectedcountis.48. 
 
  
 
 
DESCRIPTIVES 
 
 N Minimum Maximum Mean Std. 
Deviation 
NOOF DAYS OF 
ICU CARE 
Valid N (listwise) 
25 
 
 
25 
2 13 6.36 3.315 
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FREQUENCIES 
VENTILLATOR  
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid     < 1 day 
   > 1 day 
Total 
14 
11 
25 
56.0 
44.0 
100.0 
56.0 
44.0 
100.0 
56.0 
100.0 
 
 
 
 
CHOLANGITIS*VENTILLATOR 
 
 Ventillator 
 
 
Total < 1 day > 1 day 
CHOLANGITIS ABSENT       Count 
% withinVentillator 
5 
35.7% 
4 
36.4% 
9 
36.0% 
PRESENT    Count 
% withinVentillator 
9 
64.3% 
7 
63.6% 
16 
64.0% 
Total                                           Count 
% withinVentillator 
14 
100.0% 
11 
100.0% 
25 
100.0% 
 
 
 
 
  
Value 
 
df 
Asymp. 
Sig.  
(2-sided) 
Exact Sig.  
(2- sided) 
Exact Sig.  
(1- sided) 
Pearson Chi-
Square Continuity 
Correction b 
Likelihood Ratio 
Fisher's Exact Test 
N of Valid Cases 
.001a 
.000 
.001 
 
 
25 
1 
1 
1 
.973 
1.000 
.973 
 
 
 
 
 
1.000 
 
 
 
 
 
.648 
 
a.1 cells (25.0%) have expected count less than5. The minimum expected count is 
3.96. b. Computed only for a2x2 table 
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BILIRUBIN*VENTILLATOR 
 
 Ventillator 
 
 
Total < 1 day > 1 day 
BILIRUBIN INCREASED    Count 
% within Ventillator 
9 
64.3% 
10 
90.9% 
19 
76.0% 
NORMAL          Count 
% within Ventillator 
5 
35.7% 
1 
9.1% 
6 
24.0% 
Total                                        Count 
% within Ventillator 
14 
100.0% 
11 
100.0% 
25 
100.0% 
    
  
Value 
 
df 
Asymp. Sig.  
(2-sided) 
Exact 
Sig.  
(2- sided) 
Exact Sig.  
(1- sided) 
Pearson Chi-Square 
ContinuityCorrectionb 
Likelihood Ratio 
Fisher's Exact Test 
N of Valid Cases 
2.394a 
1.157 
2.603 
 
 
25 
1 
1 
1 
.122 
.282 
.107 
 
 
 
 
 
.180 
 
 
 
 
 
.141 
a.2 cells (50.0%) have expected count less than5. The minimum expected count 
is2.64. b. Computed only for a2x2 table 
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IONOTROPIC 
SUPPORT 
 
 
Total 
NO YES 
CHOLANGITIS ABSENT       Count 
% within IONOTROPIC SUPPORT 
4 
33.3% 
5 
38.5% 
9 
36.0% 
PRESENT    Count 
% within IONOTROPIC SUPPORT 
8 
66.7% 
8 
61.5% 
16 
64.0% 
Total                                           Count 
% within IONOTROPIC SUPPORT 
12 
100.0% 
13 
100.0% 
25 
100.0% 
 
 
 
 
  
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig.  
(2- sided) 
Exact Sig.  
(1- sided) 
Pearson Chi-Square 
ContinuityCorrectionb 
Likelihood Ratio 
Fisher's Exact Test 
N of Valid Cases 
.071a 
.000 
.071 
 
 
25 
1 
1 
1 
.790 
1.000 
.789 
 
 
 
 
 
1.000 
 
 
 
 
 
.560 
 
a.2 cells (50.0%) have expectedcountless than5. The minimumexpectedcountis4.32. 
b.Computedonlyfor a2x2 table 
 
 
IONOTROPICSUPPORT 
 
 IONOTROPIC 
SUPPORT 
 
 
Total 
NO YES 
BILIRUBI
N 
INCREASED    Count 
% within IONOTROPIC SUPPORT 
8 
66.7% 
11 
84.6% 
19 
76.0% 
NORMAL          Count 
% within IONOTROPIC SUPPORT 
4 
33.3% 
2 
15.4% 
6 
24.0% 
Total                                        Count 
% within IONOTROPIC SUPPORT 
12 
100.0% 
13 
100.0% 
25 
100.0% 
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Value 
 
df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2- sided) 
Exact Sig. 
(1- sided) 
Pearson Chi-Square 
Continuity 
Correction b 
Likelihood Ratio 
Fisher's Exact Test 
N of Valid Cases 
1.102a 
.338 
1.115 
 
 
25 
1 
1 
1 
.294 
.561 
.291 
 
 
 
 
 
.378 
 
 
 
 
 
.281 
 
a.2 cells (50.0%) have expected count less than5. The minimum expected count is 
2.88. b.Computed only for a2x2 table 
 
ERCP STENTED*IONOTROPICSUPPORT 
 
 IONOTROPIC 
SUPPORT 
 
 
Total 
NO YES 
ERCP 
STENTED 
NO        Count 
% within IONOTROPIC 
SUPPORT 
4 
33.3% 
12 
92.3% 
16 
64.0% 
YES      Count 
% within IONOTROPIC 
SUPPORT 
8 
66.7% 
1 
7.7% 
9 
36.0% 
Total                                      Count 
% within IONOTROPIC SUPPORT 
12 
100.0% 
13 
100.0% 
25 
100.0% 
    
 
 
Value 
 
df 
Asymp. 
Sig. 
(2-sided) 
Exact Sig. 
(2- sided) 
Exact Sig. 
(1- sided) 
Pearson Chi-
Square Continuity 
Correction b 
Likelihood Ratio 
Fisher's Exact Test 
N of Valid Cases 
9.420a 
7.034 
10.344 
 
 
25 
1 
1 
1 
.002 
.008 
.001 
 
 
 
 
 
.004 
 
 
 
 
 
.003 
a.2 cells (50.0%) have expected count less than5. The minimum expected count 
is4.32. b.Computed only for a2x2 table 
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RELAPOROTOMY  
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid     NO 
YES 
Total 
20 
5 
25 
80.0 
20.0 
100.0 
80.0 
20.0 
100.0 
80.0 
100.0 
 
BILIRUBIN=INCREASED 
 
SEPSIS *ALBUMIN 
 
 ALBUMIN  
 
Total 
DECREASED NORMAL 
SEPSIS ABSENT       Count 
% within 
ALBUMIN 
7 
43.8% 
3 
100.0% 
10 
52.6% 
PRESENT    Count 
% within 
ALBUMIN 
9 
56.2% 
0 
0.0% 
9 
47.4% 
Total                               Count 
% within 
ALBUMIN 
16 
100.0% 
3 
100.0% 
19 
100.0% 
 
a.BILIRUBIN = INCREASED 
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76 
 
 
 
 
 
 
 
  
Value 
 
df 
Asymp. Sig.   
(2-ided) 
Exact Sig. 
(2- sided) 
Exact Sig. 
(1- sided) 
Pearson Chi-Square 
ContinuityCorrectio
nc Likelihood Ratio 
Fisher's Exact Test 
N of Valid Cases 
3.206b 
1.347 
4.357 
 
 
19 
1 
1 
1 
.073 
.246 
.037 
 
 
 
 
 
.211 
 
 
 
 
 
.124 
 
a.BILIRUBIN = INCREASED b.2 cells (50.0%) have expectedcountless than5. The 
minimumexpectedcountis1.42. 
SEPSIS *ALBUMIN 
 
 ALBUMIN 
 
 
Total DECREASED NORMAL 
SEPSIS ABSENT       Count 
% withinALBUMIN 
2 
66.7% 
2 
66.7% 
4 
66.7% 
PRESENT    Count 
% withinALBUMIN 
1 
33.3% 
1 
33.3% 
2 
33.3% 
Total                               Count 
% withinALBUMIN 
3 
100.0% 
3 
100.0% 
6 
100.0% 
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a.BILIRUBIN = NORMAL 
 
 
  
Value 
 
df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2- sided) 
Exact Sig. 
(1- sided) 
Pearson Chi-Square 
Continuity 
Correction c 
Likelihood Ratio 
Fisher's Exact Test 
N of Valid Cases 
.000b 
.000 
.000 
 
 
6 
1 
1 
1 
1.000 
1.000 
1.000 
 
 
 
 
 
1.000 
 
 
 
 
 
.800 
 
a.BILIRUBIN = NORMAL b.4 cells (100.0%) have expected count less than 5. The 
minimum expected count is 1.00. c. Computed only for a2x2 tab 
 
SEPSIS *ERCPSTENTED   
 ERCP STENTED 
 
 
Total NO YES 
SEPSIS ABSENT       Count 
% within ERCP STENTED 
5 
31.2% 
9 
100.0% 
14 
56.0% 
PRESENT    Count 
% within ERCP STENTED 
11 
68.8% 
0 
0.0% 
11 
44.0% 
Total                               Count 
% within ERCP STENTED 
16 
100.0% 
9 
100.0% 
25 
100.0% 
 
 
 
  
Value 
 
df 
Asymp. Sig.  
(2-sided) 
Exact Sig.  
(2- sided) 
Exact Sig.  
(1- sided) 
Pearson Chi-
Square Continuity 
Correction b 
Likelihood Ratio 
Fisher's Exact Test 
N of Valid Cases 
11.049a 
8.435 
14.422 
 
 
25 
1 
1 
1 
.001 
.004 
.000 
 
 
 
 
 
.001 
 
 
 
 
 
.001 
 
a.1 cells (25.0%) have expected count less than5. The minimum expected count is 
3.96. b. Computed only for a 2x2 table 
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 N Minimum Maximum Mean Std. Deviation 
CA 19-9 
Valid N (listwise) 
25 
25 
19 331 161.56 115.376 
NPARTESTS 
 
KRUSKAL-WALLISTEST 
 
RANKS 
 
LOCATIONOF LESION N Mean Rank 
CA 19-9  AMPULLARY  
DISTAL CBD 
DUODENUMD2 
HEAD OF PANCREAS  
Total 
 
11 
4 
4 
6 
25 
13.18 
11.00 
16.63 
11.58 
 
Descriptives 
 
CA 19-9  
 
N Mean 
Std. 
Deviation 
AMPULLARY 
DISTAL CBD 
DUODENUMD2 
HEAD OF PANCREAS 
Total 
11 
4 
4 
6 
25 
167.64 
136.50 
227.50 
123.17 
161.56 
106.971 
124.208 
138.988 
119.717 
115.376 
 
 
Test Statisticsa,b 
 
 CA 19-
9 
Chi-
Square df 
Asymp. 
Sig. 
1.501 
3 
.682 
 
a.KruskalWallisTest 
 
b.GroupingVariable: LOCATIONOF LESI`ON 
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SUMMARY 
 Among the study group  of 25 patients  underwent pancreaticoduodenectomy 
commonest neoplasm is ampullary growth. 
 Male female ratio 2.8: 1 
 Age – commonest in our study is 6th decade.  
 In our study age group ranges from 3rd to 7th decade 
 Ampullary growth is common in males , where as in females head of pancreas 
growth is common. 
 Among study group females had higher incidence of ampullary growth when 
they enter 6th decade. 
 Most common presenting symptom is abdominal pain , followed by jaundice 
 Hyperbilirubinemia is seen in 74% of patients 
 Cholangitis is seen in 48% of patients Hypoalbuminemia seen in 76% of 
patients. 
 Hypoalbuminemia is common in ampullary neoplasms, followed by head of 
pancreas neoplasm 
 60% of patients with obstructive jaundice underwent ERCP and 35% of 
patients underwent ERCP guided stenting.  
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 12% (3 out of 25) patients had h/o previous surgery 
 Patients having preoperative cholangitis had  
-post operative septicemia 
-requires ionotropic supports  
-prolonged ventillatory support 
 Among the patients who had preoperative cholangitis ERCP stented patients 
had uneventful postoperative course 
 CA19- 9 levels elevated in 88% 0f cases  
 4%(1 patient ) received preoperative chemotherapy 
 12%of patient underwent relaporotomy, commonest indication being 
pancreatic anastomotic leak(PJ>PG ) followed by haemorrhage 
 4% of patient underwent angioembolisation for haemorrhage 
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CONCLUSION 
 Periampullary neoplasms are common in males 
 Majority of patient underwent pancreaticoduodenecomy,  commonest
            neoplasm is ampullary growth  
 Maximum age of incidence is between 60 to 70 years 
 Male female ratio 2.8: 1 
 Commonest presentation is abdominal pain and jaundice 
 CA 19 – 9 levels elevated in 88% of cases  
 Hyperbilirubinemia and hypoalbuminemia causes severe postoperative 
            morbidity 
 Patients with obstructive jaundice requires ERCP and stenting reduces 
            postoperative morbidity  
 Patients with obsructive jaundice requires prolonged ventillatory support, 
            ionotropic support 
 Patients with preoperative cholangitis had postoperative sepsis commonly  
 Commonest indication for relaporotomy is  pancreatic leak  
 (PJ>PG) 
 Preoperative preparation of patient is influences the outcome of surgery 
82
PREOPERATIVE FACTORS PREDICTING POSTOPERATIVE 
MORBIDITY IN PATIENTS WITH PERIAMPULLARY 
CARCINOMA UNDERGOING 
PANCREATICODUODENECTOMY 
 
PROFOMA 
 
NAME: 
 
AGE &SEX : 
 
OP/IP NO: 
 
DATE OF ADMISSION: 
 
CLINICAL HISTORY: 
 
                 SYMPTOMS -  
 
                 DURATION- 
 
INVESTIGATIONS: 
 
 HAEMATOLOGICAL-  
 
 CA 19-9 
 
                               TOTAL BILIRUBIN 
 
                               DIRECT BILIRUBIN 
 
                               ALBUMIN 
 
                                BLOOD CULTURE 
 
IMAGING – 
 
 PATHOLOGICAL- 
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TREATMENT  
PANCREATICODUODENECTOMY(WHIPPLE PROCEDURE) 
 
OUTCOMES: IN TERMS OF POSTOPERATIVE COURSE 
 
CLINICAL IMPROVEMENT  
 
DURATION OF ICU CARE 
 
VENTILATORY SUPPORT 
 
RELAPOROTOMY 
 
SEPSIS                   
 
DEATH                                          
 
DATE OF DISCHARGE- 
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GOVT STANLEY MEDICAL COLLEGE, CHENNAI 600 001 
 
INFORMED CONSENT 
 
DISSERTATION TOPIC:   
Preoperative factors predicting postoperative morbidity in patients 
with periampullary carcinoma undergoing 
pancreaticoduodenectomy 
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI 
NAME AND ADDRESS OF PATIENT: 
 
 
I, _____________________ have been informed about the details of the study 
in my own language. 
 
I have completely understood the details of the study. 
 
I am aware of the possible risks and benefits, while taking part in the study. 
 
I understand that I can withdraw from the study at any point of time and even 
then, I will continue to receive the medical treatment as usual. 
 
I understand that I will not get any payment for taking part in this study. 
 
I will not object if the results of this study are getting published in any medical 
journal, provided my personal identity is not revealed. 
 
I know what I am supposed to do by taking part in this study and I assure that I 
would extend my full co-operation for this study. 
 
Name / Address of the Volunteer:                                   Name / signature of investigator 
Date:                                                                    Date: 
Signature/Thumb impression of the Volunteer 
 
 
 
 
Witnesses: (Signature, Name & Address) 
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